# Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934

> **NCT02021409** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 126 (actual)

## Conditions studied

- Anemia
- Renal Insufficiency, Chronic

## Interventions

- **DRUG:** BAY85-3934
- **BIOLOGICAL:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT02021409
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-28
- **Primary completion:** 2015-10-15
- **Final completion:** 2015-11-23
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02021409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02021409, "Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02021409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*